366
Participants
Start Date
July 6, 2020
Primary Completion Date
April 1, 2026
Study Completion Date
April 1, 2026
Emavusertib
Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
Venetoclax
"Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.~This arm of the study has been closed to enrollment."
Emavusertib
Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
COMPLETED
Service d'hématologie clinique CHU de Nice, Nice
ACTIVE_NOT_RECRUITING
Albert Einstein Medical College, The Bronx
COMPLETED
University of Rochester Medical Center, Rochester
COMPLETED
Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg
COMPLETED
Novant Health Hematology - Forsyth, Winston-Salem
COMPLETED
Hospital Universitaro del a Princesa, Madrid
COMPLETED
Winship Cancer Institute, Atlanta
ACTIVE_NOT_RECRUITING
Moffitt Cancer Center, Tampa
COMPLETED
Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin, Düsseldorf
COMPLETED
The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus
COMPLETED
Universitatsklinikum Munster, Münster
COMPLETED
Karmanos Cancer Institute, Detroit
ACTIVE_NOT_RECRUITING
Northwestern Memorial Hospital, Chicago
COMPLETED
University of Chicago Medical Center, Chicago
COMPLETED
Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha
COMPLETED
APHP - Sorbonne Universite, Paris
COMPLETED
APHP - Hopital Saint Louis, Paris
ACTIVE_NOT_RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
COMPLETED
Klinikum rechts der Isar der Technischen Universitat Munchen, München
COMPLETED
Soroka University MC, Beersheba
COMPLETED
Edith Wolfson Medical Center, Holon
COMPLETED
Hadassah University MC, Jerusalem
RECRUITING
Dana Farber Cancer Institute, Boston
COMPLETED
Vseobecna Fakultni nemocnice v Praze, Prague
COMPLETED
Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I, Leipzig
COMPLETED
Azienda Ospedaliera Santa Croce e Carle, Cuneo
COMPLETED
"Instituto Romagnolo per lo Studio dei Tumori Dino Amadori", Meldola
COMPLETED
Hospital de la Santa Creu I Sant Pau (Neuvo Hospital), Barcelona
COMPLETED
MD Anderson Cancer Center Madrid, Madrid
COMPLETED
Hospital Universitario Virgen del Rocio, Seville
COMPLETED
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz, Gdansk
COMPLETED
University Hospital in Krakow, Krakow
Curis, Inc.
INDUSTRY